Approval · Notice of Compliance 18853 · 2017
ADVAIR: Notice of Compliance 18853
Issued January 6, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18853
- Date
- January 6, 2017
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update labelling to add pharmacopeial standards and creating a foil pouch label for advair diskus
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADVAIR | Not yet assigned | — |
| ADVAIR DISKUS | Not yet assigned | — |
Medicinal ingredients
- FLUTICASONE PROPIONATE 125 MCG per ACT
- SALMETEROL XINAFOATE 25 MCG per ACT
- FLUTICASONE PROPIONATE 250 MCG per ACT
- FLUTICASONE PROPIONATE 100 MCG per DOSE
- SALMETEROL XINAFOATE 50 MCG per DOSE
- FLUTICASONE PROPIONATE 250 MCG per DOSE
- FLUTICASONE PROPIONATE 500 MCG per DOSE